Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2551–2600 of 18616
the Company has appointed Mr. Fahmi Karam to succeed Mr. Fadel as Chief Executive Officer of the Company and a member of the Board, effective as of the Transition Date.
Also effective immediately, Kaes Van’t Hof, current President of Viper, will succeed Mr. Stice as Chief Executive Officer
Travis D. Stice will move on from his role as Chief Executive Officer of Viper, effective immediately; he will remain a member of the Board of Directors of Viper (the “Board”).
Kaes Van’t Hof, current President and Chief Financial Officer of the Company, will succeed Mr. Stice as Chief Executive Officer and will be nominated for election to the Board at the Company’s 2025 Annual Meeting of Stockholders.
Effective as of February 20, 2025, Jere W. Thompson III, current Executive Vice President of Strategy and Corporate Development of the Company, will assume the role of Executive Vice President and Chief Financial Officer.
On February 19, 2025, the Company announced that Larry Jasinski will step down as the Chief Executive Officer of the Company and member of the Board of Directors of the Company (the “Board”), by the end of the second quarter of 2025.
On February 13, 2025, Wenbing Chris Wang resigned as Chief Financial Officer of Nature’s Miracle Holding Inc. (the “ Company ”), effective immediately.
Barry Zwarenstein has decided to retire from his position as the Chief Financial Officer (“CFO”) of Five9, Inc. (the “Company”), effective as of March 31, 2025.
the Company announced that the Board appointed Bryan Lee, 46, the Company’s current Executive Vice President of Finance, as the Company’s Interim Chief Financial Officer and Interim Principal Financial Officer, effective as of April 1, 2025
On February 17, 2025, Steve Valenzuela, the Chief Financial Officer of the Company, announced his retirement from the Company effective June 2, 2025, which may be extended to assist in the transition to a new Chief Financial Officer.
On February 20, 2025, the Company announced that its Chief Financial Officer, Alan Taylor, plans to retire from his position at the end of the first quarter of 2025.
The Company expects to appoint Jason Christiansen, the Company’s Vice President of Finance, to succeed Mr. Taylor (the “Leadership Transition”).
Michael Thomson, the Company’s current President and Chief Operating Officer, will cease serving as the Company’s Chief Operating Officer on March 31, 2025, and will serve as the Chief Executive Officer and President and as a director of the Company, effective April 1, 2025.
the Board of Directors unanimously elected Daniel R. Wall, current President – Global Geographies, as Expeditors’ next President and Chief Executive Officer, effective April 1, 2025.
Jeffrey S. Musser, President and Chief Executive Officer, notified the Board of Directors of his plans to retire, effective March 31, 2025.
On February 18, 2025, ServisFirst Bancshares, Inc. (the “Company”) announced the appointment of David Sparacio, 54, as Executive Vice President and Chief Financial Officer of ServisFirst Bank (the “Bank”).
In connection with the appointments of Mr. Villanova to CFO and Ms. Stalick to CAO, each as previously reported
will retire as Chief Executive Officer of the Company effective January 1, 2026.
will become the new Chief Executive Officer upon Mr. Moghadam’s retirement effective January 1, 2026.
The Board appointed the Company’s Chief Executive Officer, Barry Gosin, as Principal Executive Officer of the Company following Howard Lutnick’s confirmation as the 41st Secretary of Commerce and departure from the Company.
Howard Lutnick, Chairman of the Board of Directors (the “Board”) and Chief Executive Officer of BGC Group, Inc. (“BGC” or the “Company”), informed the Company that he has stepped down as Chairman of the Board and Chief Executive Officer of the Company, effective February 18, 2025
Stephan Paulo Gratziani, the Company’s current President, was appointed as the Company’s Chief Executive Officer, effective May 1, 2025
On the same day, the Board of Directors (the “Board”) of the Company appointed Bonnie-Jeanne Gerety as Interim Chief Executive Officer.
On February 14, 2025, in connection with the Company’s ongoing bankruptcy cases, the Board made the decision to terminate all Company employees, including all executive officers except for Winston Mar of CR3 Partners, the Company’s Chief Restructuring Officer.
As of February 12, 2025, The Board of Directors of PNXP accepted the Resignation of Mr. Matthew Feinstein as Chief Executive Officer "CEO", President, Directors and Chairman of the Board.
As of February 12, 2025, The Board of Directors of PNXP accepted the appointment of Mr. Franjose "Frank" Yglesias as Chief Executive Officer "CEO", President, Directors and Chairman of the Board.
the Board appointed Paul Edmondson as interim Chief Executive Officer.
terminated the employment of Sara Silverstein, the Company’s Chief Executive Officer, without cause, effective the same day.
(As previously announced, Mr. Spiegel will transition from his role as Chief Financial Officer on March 1, 2025.)
Appointment of John H. Lee as Chief Financial Officer On February 13, 2025 , NerdWallet, Inc. (the Company) appointed Jun Hyung Lee (aka John H. Lee) (age 39) as Chief Financial Officer (CFO) of the Company, effective March 17, 2025.
The Company has appointed Nicholas Tatum (age 40), the Company’s Corporate Controller, as Chief Accounting Officer and principal accounting officer, effective March 8, 2025.
On February 13, 2025, the Company appointed Chao Li to serve as Chief Financial Officer of the Company.
On February 13, 2025, the Company appointed Juan Yang to serve as Chief Executive Officer, Treasurer and Secretary of the Company.
will transition from his role as Chief Financial Officer on March 1, 2025.
Under the Consulting and Transition Agreement, Mr. Akright will serve as a fractional Chief Financial Officer to the Company, and will continue to serve as the Company's principal financial and accounting officer.
Mr. Sarner resigned from his positions of Chief Financial Officer, Chief Compliance Officer and Secretary of the Company, effective immediately.
the Board also promoted Chris Rehberger, Executive Vice President of Finance and Treasurer of the Company, to the positions of Chief Financial Officer, Treasurer and Secretary of the Company, effective immediately.
Bowen S. Diehl notified the Board that he was stepping down as the President and Chief Executive Officer of the Company and as a director of the Board.
On February 17, 2025, the Board appointed Michael S. Sarner, the Chief Financial Officer, Chief Compliance Officer and Secretary of the Company, to succeed Mr. Diehl as the President and Chief Executive Officer of the Company, effective immediately.
On February 14, 2025, the Board elected Mr. Mike Stepniak, age 47, to serve as the Company’s Senior Vice President and Chief Financial Officer, effective as of February 17, 2025.
On February 14, 2025, the Board appointed Martin Rodgers to the position of Chief Financial Officer of the Company.
On February 14, 2025, Mr. Umesh Mahajan, Co-Chief Investment Officer, Chief Financial Officer and Secretary of the Company, resigned from his position as Chief Financial Officer of the Company.
Katrina Sparano retired as the Company’s Chief Financial Officer and Treasurer effective February 15, 2025.
Kaitlyn O’Neil was appointed as the Company’s new Principal Financial Officer and Treasurer, effective such date.
Effective February 13, 2025, Milton H. Werner, Ph.D. resigned as President, Chief Executive Officer and principal executive officer of Inhibikase Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company (the “Resignation”).
Effective February 14, 2025, the Board appointed Mark Iwicki as President, Chief Executive Officer and principal executive officer of the Company (the “Appointment”).
Mr. LaRose became a full-time non-officer employee of the Company, and is expected to remain employed for a transition period ending on April 30, 2025.
appointed Sabrina Simmons to succeed Brian LaRose as the Company’s Chief Financial Officer (the “CFO Succession”), effective as of February 17, 2025
On February 14, 2025, the Board appointed Frank Karbe, 56, as the Company’s Chief Financial Officer (including as its principal financial officer and principal accounting officer), effective as of Mr. Karbe’s employment start date, which is expected to be February 24, 2025
On February 12, 2025, Cidara Therapeutics, Inc. (the “Company”) and Preetam Shah, Ph.D., MBA., the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, mutually agreed to Dr. Shah’s separation from such roles with the Company, effective February 24, 2025
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.